IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I would have to agree that the company is in a much better position.
Although we were told more would come shortly at the 16th Oct Investor on reproductive health we also know via the product route map that by 2020-21 (when the new Illumina CE-IVD will also be launched) the product range will also include by then the following:
a) Pre-implantation genetic screening (PGS) – a technique for testing whether embryos have any problems with their chromosomes, which is thought to be the most common reason why IVF treatment fails.
b) Rhesus disease screens in which DNA from the unborn baby, found in the mother's blood, can be tested to determine if the foetus is at risk from the mother’s antibodies (when the mother’s blood is rhesus-negative and the foetus is rhesus-positive), which can destroy the red blood cells, causing jaundice, anaemia, miscarriage or stillbirth.
c) BRAC1 screens to pre-determine if a foetus is at risk of inheriting an altered (mutated) BRCA1 gene, which has been shown to increase a woman's chance of developing breast cancer and ovarian cancer.
Although the new Illumina test will only come in 2020, Premaitha has ALREADY taken a licence under Illumina’s patent pool agreement (PPA). This is important as PPA patents were pending in Brazil and India so clears. It allows Premaitha to also offer Illumina NGS lab services in interim to access the 80% of market on Illumina NGS. The Illumina CE-IVD would however I think allow Premaitha to expand more freely into US, Mexico and Australia. NOW through the settlement, in any non-PPA licensed territory (majority of Asia, Middle East, Africa and the Americas) Premaitha is free to be platform-agnostic providing tests for use on both Thermo Fisher and Illumina NGS platforms.
It should also be observed than compared to some stocks which have very much higher market capitalisations, Premaitha actually has a multitude of products already on the shelf.
The additional revenue streams above have yet to be included in the broker's revenue projections which pessimistically though DID include a softening of growth till the new CE-IVD. The unleashing of 80% opportunity referred (plus now free access to US, AUS, MEX) plus the additional products above apparently only provided 25% growth to £11.9m in the broker's forecast for 2021E. But I remain 'idealistic' that these revenue projections will be updated.
Despite these projections, which the Company has already distanced itself from, I note that in December 2016 Agilent Technologies bought Multiplicom for $72.8m. At the time Multiplicom had $6.5m sales so 11.2x EV/Sales. Hence suggesting that the current sp which is now heavily discounted.
On a side note there was an additional 400k shares bought this week at the placing price of 10p by an II separate to AR's additional 500k subscription. Given that Steve Myers passed the 8% threshold on the 23rd I suspect it was him. Hopefully we should recover to this placing price shortly and then mov